ERBB2 and neoplasm: Recent data from the GeparX clinical trial showed that RANK expression in tumor cells was an independent predictive biomarker of response to neoadjuvant chemotherapy in luminal breast cancer, highlighting the opposite in TNBC and HER2-positive tumors [28].